Cyclin D1 and t(11;14): The Defining Biomarker of Mantle Cell Lymphoma

Introduction

Among the small B-cell lymphomas, few diagnostic distinctions carry as much practical weight as separating mantle cell lymphoma (MCL) from chronic lymphocytic leukemia (CLL) and other CD5-positive small B-cell neoplasms. These entities can look deceptively similar under the microscope and share overlapping immunophenotypes, yet they behave differently and are managed along different pathways. The biomarker that resolves this ambiguity is nuclear cyclin D1 overexpression, driven in the great majority of cases by the chromosomal translocation t(11;14)(q13;q32). This article explains what this biomarker measures, how it is assessed, and what each result means for diagnosis and treatment eligibility.

What the Test Measures

Cyclin D1 (encoded by CCND1) is a regulatory protein that governs progression through the G1 phase of the cell cycle. In normal mature B cells, cyclin D1 is not expressed. In MCL, the hallmark genetic event is t(11;14)(q13;q32), which juxtaposes CCND1 on chromosome 11 with the immunoglobulin heavy chain (IGH) enhancer on chromosome 14. This IGH::CCND1 fusion places CCND1 under the control of powerful immunoglobulin regulatory elements, driving constitutive overexpression of cyclin D1 protein and the cell-cycle dysregulation that characterizes the disease [1][3].

Because aberrant nuclear cyclin D1 is essentially absent from normal B cells and from most other small B-cell lymphomas, its detection functions as a near-specific marker of MCL. The current WHO and International Consensus classifications treat nuclear cyclin D1 expression and/or the t(11;14) translocation as defining features of the entity [1][2][3].

How It Is Tested

Two complementary assays are used, both performed on formalin-fixed, paraffin-embedded (FFPE) tissue.

Immunohistochemistry (IHC) for cyclin D1 is the frontline method. The scoring readout is nuclear positivity in the neoplastic B cells. This nuclear localization is essential to interpretation—cytoplasmic blush or staining of scattered non-neoplastic cells (endothelium, histiocytes, proliferating cells) should not be mistaken for a positive tumor result. As with all IHC, preanalytic factors matter: adequate and prompt fixation, appropriate antigen retrieval, and validated antibody clones influence sensitivity and specificity. Suboptimal fixation can weaken or obscure genuine nuclear signal.

Fluorescence in situ hybridization (FISH) using an IGH::CCND1 dual-fusion or break-apart strategy directly demonstrates the t(11;14) translocation. FISH is valuable when IHC is equivocal, when staining is technically compromised, or when a cyclin D1–negative MCL is suspected on clinical and morphologic grounds. Detecting the translocation provides orthogonal, genetic-level confirmation of the diagnosis [1][3].

In practice, the two assays reinforce one another: IHC offers a rapid, morphology-anchored screen, and FISH provides definitive genetic evidence.

What Each Result State Means

Cyclin D1–positive / t(11;14)–positive. This is the classic and most common profile. In the appropriate morphologic and immunophenotypic context—typically a CD5-positive, small B-cell proliferation—nuclear cyclin D1 expression together with (or corroborated by) the t(11;14) translocation establishes the diagnosis of mantle cell lymphoma [1][2][3]. This combination is what most reliably distinguishes MCL from CLL and other CD5-positive small B-cell lymphomas.

Cyclin D1–negative MCL (rare). A minority of genuine MCL cases do not overexpress cyclin D1 and lack detectable t(11;14). These are recognized in current classifications and are typically driven by alternative mechanisms, including SOX11 expression and translocations involving CCND2 or CCND3 [1][2]. In this setting, cyclin D1 IHC and CCND1 FISH will be negative, and the diagnosis rests on integrating morphology, immunophenotype, and surrogate markers such as SOX11. Awareness of this variant is critical, because a negative cyclin D1 result does not by itself exclude MCL when the overall picture is suggestive.

What It Determines for Treatment Eligibility

The central role of this biomarker is diagnostic classification, and that classification, in turn, directs which therapeutic pathways are applicable. By securing the diagnosis of MCL and separating it from CLL and other CD5-positive small B-cell lymphomas, cyclin D1/t(11;14) testing informs eligibility for MCL-directed therapy rather than the regimens used for those other entities [1][2][3].

It is important to frame this correctly: the biomarker establishes which disease category a patient's lymphoma belongs to, thereby determining which drug classes are appropriate to consider. It does not, on its own, dictate a specific treatment for any individual, and nothing in this article should be read as treatment advice. Management decisions rest with the treating clinical team, integrating stage, patient factors, and additional pathology.

Caveats and What Is Evolving

Several points warrant caution. First, interpretation is context-dependent: cyclin D1 expression must be read in the nucleus of the neoplastic population and correlated with morphology and immunophenotype, since technical artifacts and non-neoplastic staining can mislead. Second, the existence of cyclin D1–negative MCL means a negative IHC result cannot exclude the diagnosis when clinical suspicion is high; recognition of the SOX11/CCND2/CCND3 biology underlying these cases is essential to avoid misclassification [1][2][3].

The evidence suggests that as classification frameworks mature, the molecular definition of MCL—particularly the cyclin D1–negative subset and its surrogate markers—continues to be refined across the WHO and ICC systems [1][2]. Pathologists should be attentive to the specific criteria and definitions applied in their reporting environment, and to the complementary use of IHC and FISH to resolve ambiguous cases.

Conclusion

Nuclear cyclin D1 overexpression and the t(11;14) IGH::CCND1 translocation together constitute the defining biomarker of mantle cell lymphoma. Assessed by IHC and FISH on FFPE tissue and interpreted within the full morphologic and immunophenotypic context, this biomarker separates MCL from CLL and other CD5-positive small B-cell lymphomas and thereby informs eligibility for MCL-specific therapeutic classes. Recognizing the rare cyclin D1–negative variant remains a key safeguard against diagnostic error.

References

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01620-2

2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms. Blood. 2022. doi:10.1182/blood.2022015851

3. Jares P, et al. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Nuclear Cyclin D1 as Defining Features. Frontiers in Oncology / PMC7461610. 2020. PMCID: PMC7461610